SURVIVAL BENEFIT OF NEOADJUVANT CHEMOTHERAPY IN RESECTABLE PANCREATIC CANCER - NEED BOTH ENDS OF THE SANDWICH

被引：0
|
作者：
Kim, Rachel C.
Allen, Kara A.
Roch, Alexandra M.
Butler, James
Ceppa, Eugene P.
House, Michael G.
Zyromski, Nicholas J.
Nakeeb, Attila
Schmidt, C. Max
Nguyen, Trang
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1172
引用
收藏
页码：S1510 / S1510
页数：1
相关论文
共 50 条
  • [1] Survival Benefit of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer - Need Both Ends of the Sandwich
    Kim, Rachel C.
    Allen, Kara A.
    Roch, Alexandra M.
    Butler, James
    Ceppa, Eugene P.
    House, Michael G.
    Zyromski, Nicholas
    Nakeeb, Attila
    Schmidt, C. Max
    Nguyen, Trang K.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S158 - S158
  • [2] Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer
    Waugh, Evelyn
    Glinka, Juan
    Breadner, Daniel
    Liu, Rachel
    Tang, Ephraim
    Allen, Laura
    Welch, Stephen
    Leslie, Ken
    Skaro, Anton
    ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2024, 28 (02) : 229 - 237
  • [3] Neoadjuvant chemotherapy in resectable pancreatic cancer
    Irmscher, Sabrina
    Senninger, Norbert
    Schleicher, Christina
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (07) : 2059 - 2060
  • [4] Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer
    Sabrina Irmscher
    Norbert Senninger
    Christina Schleicher
    Annals of Surgical Oncology, 2008, 15 : 2059 - 2060
  • [5] Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer
    Daniel H. Palmer
    Deborah D. Stocken
    Helen Hewitt
    Catherine E. Markham
    A. Bassim Hassan
    Philip J. Johnson
    John A. C. Buckels
    Simon R. Bramhall
    Annals of Surgical Oncology, 2008, 15 : 2061 - 2061
  • [6] Benefit of neoadjuvant chemotherapy for resectable gastric cancer
    Chorna, N.
    Lukashenko, A.
    Ostapenko, Y.
    Kolesnik, O.
    Boiko, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
    Chen, Yan
    Shi, Xiu-E
    Tian, Jin-Hui
    Yang, Xu-Juan
    Wang, Yong-Feng
    Yang, Ke-Hu
    MEDICINE, 2018, 97 (20)
  • [8] No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer
    Liu, Hao
    D'Alesio, Mark
    AlMasri, Samer
    Hammad, Abdulrahman
    Desilva, Annissa
    Lebowitz, Steven
    Rieser, Caroline
    Ashwat, Eishan
    Hampton, Erica
    Khachfe, Hussein
    Laffey, Mckenna
    Singhi, Aatur
    Bahary, Nathan
    Lee, Kenneth
    Zureikat, Amer
    Paniccia, Alessandro
    HPB, 2023, 25 (05) : 521 - 532
  • [9] Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
    Fossaert, Violette
    Mimmo, Antonio
    Rhaiem, Rami
    Rached, Linda J.
    Brasseur, Mathilde
    Brugel, Mathias
    Pegoraro, Francesca
    Sanchez, Stephane
    Bouche, Olivier
    Kianmanesh, Reza
    Piardi, Tullio
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
    Versteijne, Eva
    de Hingh, Ignace H. J. T.
    Homs, Marjolein Y. V.
    Intven, Martijn P. W.
    Klaase, Joost M.
    van Santvoort, Hjalmar C.
    de Vos-Geelen, Judith
    Wilmink, Johanna W.
    van Tienhoven, Geertjan
    FRONTIERS IN ONCOLOGY, 2022, 11
12345